. Author manuscript; available in PMC: 2013 Jun 17.

Published in final edited form as: Int J Clin Rheumtol. 2011;6(4):453–462. doi: 10.2217/IJR.11.29

Table 2.

Demographics of patients enrolled in RAVE and RITUXVAS.

	RAVE	RITUXVAS
Median age (years)	54	68
Male (%)	46	52
*Disease process*
Granulomatosis with polyangiitis (%)	75	55
Microscopic polyangiitis (%)	24	36
Renal involvement (%)	66	100
*ANCA positivity*
PR3-ANCA (%)	66	61
MPO-ANCA (%)	33	39

ANCA: Antineutrophil cytoplasmic autoantibodies; RAVE: Rituximab for ANCA-associated vasculitis; RITUXVAS: Rituximab versus cyclophosphamide in ANCA-associated vasculitis.

Data taken from [55,56].